What is a stock summary page? Click here for an overview.
Business Description
ARS Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US82835W1080
Description
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7476.71 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 8.58 | |||||
| Beneish M-Score | 2650.83 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 145.3 | |||||
| 3-Year EBITDA Growth Rate | 47.3 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 57.01 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 58.6 | |||||
| 9-Day RSI | 58.82 | |||||
| 14-Day RSI | 57.25 | |||||
| 3-1 Month Momentum % | -5.08 | |||||
| 6-1 Month Momentum % | -20.83 | |||||
| 12-1 Month Momentum % | 25.2 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 14.26 | |||||
| Quick Ratio | 14.04 | |||||
| Cash Ratio | 13.4 | |||||
| Days Inventory | 1107.14 | |||||
| Days Sales Outstanding | 18.32 | |||||
| Days Payable | 1719.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | 0.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 98.9 | |||||
| Operating Margin % | -3.46 | |||||
| Net Margin % | 8.97 | |||||
| FCF Margin % | 14.57 | |||||
| ROE % | 3.55 | |||||
| ROA % | 3.2 | |||||
| ROIC % | -38.78 | |||||
| 3-Year ROIIC % | 123.95 | |||||
| ROC (Joel Greenblatt) % | -311.6 | |||||
| ROCE % | -1.29 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 184.14 | |||||
| PE Ratio without NRI | 184.14 | |||||
| PS Ratio | 17.23 | |||||
| PB Ratio | 4.88 | |||||
| Price-to-Tangible-Book | 5.04 | |||||
| Price-to-Operating-Cash-Flow | 223.67 | |||||
| EV-to-EBIT | -291.21 | |||||
| EV-to-EBITDA | -291.21 | |||||
| EV-to-Revenue | 10.07 | |||||
| EV-to-Forward-Revenue | 6.96 | |||||
| EV-to-FCF | 82.92 | |||||
| Price-to-Graham-Number | 6.41 | |||||
| Price-to-Net-Current-Asset-Value | 5.22 | |||||
| Price-to-Net-Cash | 5.7 | |||||
| Earnings Yield (Greenblatt) % | -0.34 | |||||
| FCF Yield % | 1.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SPRY
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ARS Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 89.149 | ||
| EPS (TTM) ($) | 0.07 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 62.27 | ||
| 14-Day RSI | 57.25 | ||
| 14-Day ATR ($) | 0.965091 | ||
| 20-Day SMA ($) | 11.367 | ||
| 12-1 Month Momentum % | 25.2 | ||
| 52-Week Range ($) | 7.55 - 18.51 | ||
| Shares Outstanding (Mil) | 98.12 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
ARS Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
ARS Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
ARS Pharmaceuticals Inc Frequently Asked Questions
What is ARS Pharmaceuticals Inc(SPRY)'s stock price today?
The current price of SPRY is $12.89. The 52 week high of SPRY is $18.51 and 52 week low is $7.55.
When is next earnings date of ARS Pharmaceuticals Inc(SPRY)?
The next earnings date of ARS Pharmaceuticals Inc(SPRY) is 2025-05-09 Est..
Does ARS Pharmaceuticals Inc(SPRY) pay dividends? If so, how much?
ARS Pharmaceuticals Inc(SPRY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers